Andrea is currently Chief Medical Officer, R&D Head and co-founder of Orchard Therapeutics, a late clinical stage potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders. Prior to joining Orchard Therapeutics, Andrea served as VP and Medicine Development Leader at GSK Rare Diseases Unit. Previous to joining the GSK Rare Diseases Unit, Andrea was Senior Medical Director at the Immune Inflammation Discovery Performance Unit. Before GSK, Andrea was Global Medical Director R&D at Takeda in the metabolic and cardiovascular area and in charge of the paediatric developments for Takeda Europe R&D. Before that, she worked as Research Physician at Hammersmith Medical Research. Before moving to the pharmaceutical industry Andrea practiced as a paediatrician for 12 years in Argentina, Spain and UK.
Andrea obtained her MD degree from the University of Buenos Aires (UBA) and completed residency in paediatrics and post graduate training in paediatric immunology at the Dr Elizalde Children's Hospital in Buenos Aires, Argentina. She obtained a Specialist in Pharmaceutical Medicine degree from University of Basel, Switzerland and she is a Fellow of the Faculty of Pharmaceutical Medicine in London, UK (FFPM).